Estradiol Test · Blood

If you are a woman approaching or past menopause, struggling with fertility, or simply want to understand how your hormones are affecting your cardiovascular and bone health, estradiol is the single most informative estrogen measurement you can order. It is the dominant estrogen during your reproductive years, and its decline after menopause is tightly linked to accelerating bone loss, shifting fat distribution, and rising heart disease risk.

Estradiol (17-beta estradiol, often abbreviated E2) is not just a reproductive hormone. It shapes how your brain processes mood, how your blood vessels relax, and how your bones maintain their density. A single blood draw can tell you where you stand, but tracking your trend over time tells you far more.

What Estradiol Is and Where It Comes From

Estradiol is a steroid hormone, meaning it is built from cholesterol. It is the most biologically active of the three main estrogens your body produces (the others being estrone and estriol). In premenopausal women, the ovaries are the primary source: specialized cells called granulosa cells convert androgen precursors into estradiol under the direction of FSH (follicle stimulating hormone). Men produce smaller amounts through conversion of testosterone in the testes, fat tissue, and brain.

After menopause, the ovaries largely stop producing estradiol. The body's remaining estrogen comes mostly from fat tissue converting androgens into estrone, a weaker estrogen. This shift explains why body composition matters so much for postmenopausal estrogen levels: women with more body fat tend to have higher residual estrogen after menopause.

Heart Disease and Blood Vessel Health

The relationship between estradiol and heart disease is not straightforward. In postmenopausal women, higher circulating estradiol has been linked to greater risk of blocked arteries supplying the heart and brain. In a study of over 9,200 older postmenopausal women followed for four years, each standard deviation increase in estradiol was associated with about 40% higher risk of ischemic arterial disease (blockages in heart or brain arteries), even after accounting for weight, diabetes, blood pressure, cholesterol, and smoking.

In men, the picture reverses. A study of about 950 young and middle aged American men found that those with low estradiol or low free estradiol had a significantly higher risk of dying from cardiovascular disease. This suggests estradiol plays a protective role in male cardiovascular health at younger ages.

Timing also matters for women. A landmark randomized trial of 643 healthy postmenopausal women (the ELITE trial) showed that oral estradiol started within six years of menopause slowed the buildup of plaque in the carotid arteries. But the same treatment started 10 or more years after menopause had no benefit. This "window of opportunity" is one of the most clinically actionable findings in estrogen research.

Breast Cancer Risk

Among postmenopausal women, higher endogenous estradiol within the "normal" range is consistently associated with higher breast cancer risk. In a large prospective study of over 14,000 postmenopausal women, those in the highest quartile of circulating estradiol and estrone had roughly two to three times the odds of developing breast cancer compared to women in the lowest quartile. In a separate cohort of nearly 8,800 Chinese breast cancer patients, higher estradiol at diagnosis was associated with worse outcomes in both premenopausal and postmenopausal women.

A Mendelian randomization study (a genetic approach that mimics a natural experiment) involving nearly two million women found that genetically higher estradiol was associated with increased risk of estrogen receptor positive breast cancer and endometrioid endometrial cancer, but not with most other cancer types. This genetic evidence strengthens the case that estradiol itself, not just factors correlated with it, drives these particular cancer risks.

Bone Health

Estradiol is one of the strongest regulators of bone turnover. It slows down the cells that break bone apart and supports the cells that build new bone. When estradiol drops sharply at menopause or in conditions like Turner syndrome (a genetic condition where one X chromosome is missing or altered) or pituitary hormone deficiency, bone loss accelerates. Estrogen replacement in these settings improves bone density and is a standard part of treatment.

Mood and Brain Health

Estradiol influences the brain's serotonin system, which is central to mood regulation. In a randomized trial of 56 women with a history of perimenopausal depression, experimentally withdrawing estradiol (after a stabilization period on hormone therapy) triggered depressive symptoms in those with prior sensitivity, but not in controls. A separate trial of 172 perimenopausal and early postmenopausal women showed that transdermal estradiol plus progesterone prevented new depressive episodes over 12 months compared to placebo.

For cognition, the evidence is less encouraging. The same ELITE trial that showed vascular benefits found no meaningful difference in memory or executive function from oral estradiol, regardless of whether it was started early or late after menopause. A meta analysis of reproductive factors and dementia found that higher estradiol was associated with about 46% higher risk of dementia or cognitive decline in women, though this pooled estimate combines studies of varying quality.

Heart Failure: Sex Differences

A large UK Biobank study of over 358,000 adults followed for about 11 years found opposing patterns in men and women. Men in the highest quartile of free estradiol had about 24% lower risk of heart failure compared to the lowest quartile. Premenopausal women in the highest quartile, by contrast, had roughly double the risk. These findings underscore that estradiol's effects are highly sex and context dependent.

Reference Ranges

Estradiol levels vary enormously depending on your sex, age, menstrual cycle phase, and menopausal status. A single number means nothing without that context. The most reliable reference ranges come from studies using LC-MS/MS (a highly accurate lab method), but many commercial labs still use less precise immunoassays that can overestimate levels, especially in the low ranges seen in men and postmenopausal women. Always compare your results within the same lab and method over time.

These ranges are drawn from a large Danish LC-MS/MS study of 1,838 healthy individuals aged 3 months to 61 years, and from a systematic review establishing a mean postmenopausal baseline of about 3.9 pg/mL (range undetectable to 10.7 pg/mL). Your lab may use different units (pmol/L is common outside the US; to convert, multiply pg/mL by 3.67). Ethnicity also affects levels: a study collecting daily blood samples across full menstrual cycles from 27 African American and 27 Caucasian women found that estradiol was significantly higher in African American women, with the largest differences in the late follicular and mid-luteal phases.

When Results Can Be Misleading

Estradiol has moderate to high biological variability. In men and postmenopausal women, the within-person coefficient of variation (a measure of how much your level bounces around from week to week even when nothing has changed) is about 14%. In cycling premenopausal women, it jumps to about 38%, largely because of the menstrual cycle itself. This means a single reading can easily be 15 to 40% off from your "true" baseline.

• Menstrual cycle timing: In premenopausal women, estradiol can differ by several hundred percent between the early follicular phase and the ovulatory peak. A result drawn on day 3 of your cycle and one drawn on day 13 are not comparable. If you are cycling, test in the same phase each time (early follicular, days 2 to 5, is the most stable window).
• Body weight and fat mass: In postmenopausal women, higher BMI correlates with higher estradiol because fat tissue produces estrogen. This is a real biological effect, not an artifact, but it means that weight changes will shift your number.
• Hormonal medications: Oral contraceptives, hormone therapy, vaginal estrogen, progestins, and tamoxifen all change estradiol levels or alter how your body processes the hormone. If you are on any of these, your result reflects the drug plus your biology, and cannot be interpreted as your "natural" level.
• Assay type: Some immunoassay platforms produce falsely elevated estradiol readings at low concentrations due to cross reactivity with other steroids. If your result seems inconsistent with your clinical picture, ask whether your lab uses LC-MS/MS, which is the gold standard at low levels.

Tracking Your Trend

A single estradiol value is a snapshot, and a potentially misleading one. Given a 14% week-to-week variation in stable individuals and much higher variation in cycling women, two or three readings taken under consistent conditions (same lab, same time of day, same cycle phase if applicable) give you a far more reliable picture. If you are making a change, whether starting hormone therapy, adjusting a dose, or implementing a lifestyle intervention, retest in 8 to 12 weeks to see if your number has moved.

For men and postmenopausal women, at least two fasting morning measurements spaced a few weeks apart are recommended before drawing conclusions. For premenopausal women, aim for two to three measurements in the same menstrual phase across different cycles. Track annually once you have a stable baseline, or more frequently during hormonal transitions like perimenopause.

What to Do With an Abnormal Result

If your estradiol comes back unexpectedly high or low, the first step is to confirm it. Retest under the same conditions. If the result holds, the next steps depend on your situation.

• Low estradiol in a premenopausal woman: Order FSH (follicle stimulating hormone) and LH (luteinizing hormone) to distinguish between ovarian failure (high FSH) and a brain-level signaling problem (low or normal FSH). AMH (anti-Mullerian hormone) adds information about egg reserve. An endocrinologist or reproductive endocrinologist is the right specialist.
• High estradiol in a postmenopausal woman not on hormones: Consider whether body weight is driving peripheral estrogen production. Check liver function (the liver metabolizes estrogen). If unexplained, a gynecologist or endocrinologist can evaluate for ovarian or adrenal sources.
• Low estradiol in a man with cardiovascular risk factors: Pair with total testosterone, free testosterone, and SHBG (sex hormone binding globulin) to assess the full hormonal picture. Low estradiol in the context of low testosterone may warrant endocrine evaluation.
• Estradiol monitoring on hormone therapy: If your level is persistently below the expected range for your dose and route, discuss dose adjustment or a switch from patch to gel (or vice versa) with your prescriber. A real-world study of 1,508 women on transdermal estradiol found that about 25% on the highest licensed dose had levels below 200 pmol/L (about 54 pg/mL), which was flagged as potentially subtherapeutic.